ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1610

Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India

Sandeep Surendran1, Mithun CB1, Arun Tiwari2, Vishal Marwaha1 and Sekhar Easwar1, 1Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, 2Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India

Meeting: ACR Convergence 2020

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Drug toxicity, Health Services Research, risk factors, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning tools have emerged as a promising option for predicting various outcomes. The aim of our study was to use “traditional” multivariate analysis along with novel machine learning (ML) methodology to analyze and predict for the occurrence of cutaneous side effects with HCQ usage.

Methods: Demographic, clinical details, laboratory parameters, treatment details of HCQ (dose/mg/kg, cumulative dose, duration of therapy) and coexistent DMARD prescription were collected for patients who were treated with HCQ for autoimmune rheumatic diseases from 2015 to 2019. Development of cutaneous side effects was the primary outcome of the study and the subtypes of cutaneous side effect were also noted (hyperpigmentation, photosensitivity and pruritus) retrospectively. Univariate and multivariate logistic regression for the primary outcome was done using SPSS 20.0. To develop the ML classification models for prediction of the primary outcome, we used Random Forest, Logistic Regression and K-nearest neighbour (KNN)  algorithms from Python-3.0’s scikit library. Hyperparameter tuning and five-fold cross validation were done for all three ML classifiers. After the three classifer models were trained, they were compared using accuracy scores on the test dataset. Precision and area under ‘receiver operating curve’ (AUC) of the highest accuracy model were also analyzed.

Results: Baseline characteristics of the 430 participants recruited are shown in Figure 1(A). 198 patients (46.04%) developed cutaneous side effects of which the most common was hyperpigmentation (n =182, 42.3%).15 patients stopped HCQ due to the cutaneous side effects.  Figure 1(A) also shows the results of the univariate and multivariate regression analysis for development of cutaneous side effects. The risk factors identified were the cumulative dose of HCQ > 216,000 mg  (OR 1.82, 1.22-2.73), combination treatment with MMF(OR 2.13, 1.10-4.09), or AZA(OR 2.05, 1.04-4.01) ANA positive (OR 1.72, 1.06-2.8), and RF positive(OR 2.38, 1.51-3.76) . Accuracy scores of three ML models are shown in figure 2A, with the KNN classifier model having the best performance. It achieved a 62.79% accuracy with precision of 0.6 and AUC of  0.64 (figure 2B).

Conclusion: Cutaneous side effects are common with HCQ treatment. While traditional statistical methods can help identify the risk factors, usage of supervised ML methods could help predict development of cutaneous side effects in an individual patient. Larger dataset analysis could allow for development of tailored therapeutic regimens avoiding adverse events.

Figure 1

Figure 2


Disclosure: S. Surendran, None; M. CB, None; A. Tiwari, None; V. Marwaha, None; S. Easwar, None.

To cite this abstract in AMA style:

Surendran S, CB M, Tiwari A, Marwaha V, Easwar S. Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/cutaneous-side-effects-of-hydroxychloroquine-in-rheumatic-diseases-combination-of-traditional-multivariate-analysis-for-risk-factors-andclassification-model-development-usin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cutaneous-side-effects-of-hydroxychloroquine-in-rheumatic-diseases-combination-of-traditional-multivariate-analysis-for-risk-factors-andclassification-model-development-usin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology